PLX-61639

N/A

Report date: 2025/12/17 20:02:10
NME

Base Information

Drug NamePLX-61639
Drug Alias NamePLX-61639PLX61639
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionProbable global transcription activator SNF2L2 degraders
TargetsProbable global transcription activator SNF2L2
Therapy Area/IndicationsEsophageal adenocarcinomaSolid tumoursCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPlexium Inc
China Registration ClassN/A

Develop Information

Active CompaniesPlexium Inc
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaSolid tumoursCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A